RBCC May Enter $142-Billion Drug Delivery Market
As part of the company’s push to carve out a share of the $142-billion US drug delivery market, Rainbow Coral Corp. opened talks this week to potentially partner with an emerging innovator in the transdermal delivery sector.
Transdermal patches are an increasingly popular drug delivery system that is being developed for everything from contraception to Parkinson’s disease. Transdermal drug delivery prevents many of the problems associated with oral and intravenous routes and offer major advantages, such as improved bioavailability, more uniform plasma levels, longer duration of action, reduced side effects, and improved therapy.
Some analysts have predicted that the transdermal delivery market could be worth as much as $31.5 billion by 2015 from a value of $21.5 billion just 3 years ago. RBCC expects that partnering with an emerging leader in the sector could help the company capture a big piece of that growth.
“Transdermal patches offer a non-invasive option for treating many diseases and disorders,” said RBCC CEO Patrick Brown. “The appeal is obvious. We’re in negotiations now with a patch developer we believe has high profit potential, and we’re optimistic that a deal can be struck soon.”
RBCC formed a biotech subsidiary, Rainbow BioSciences, to market and develop new medical and research technology innovations to compete alongside companies, such as Bristol Myers Squibb Co., Biogen Idec Inc., Abbott Laboratories, and Amgen Inc. For more information on RBCC’s other biotech initiatives, visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on its growth-oriented business initiatives, please visit www.RainbowBioSciences.com.
Total Page Views: 944
